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RRx-001 followed by platinum plus etoposide in patients
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Karen G. Zeman6, Arvinda Padmanabhan7, JoAnn Hirth8, Alexander I. Spira9, Jane B Trepel10 and Sukhmani K. Padda11
BACKGROUND: This exploratory single-arm phase II study evaluated the efficacy and safety of RRx-001 followed by reintroduction
of platinum plus etoposide in patients with previously treated small-cell lung cancer (SCLC).
METHODS: Patients were treated with RRx-001 4mg IV on day 1 of each week of a 21-day cycle followed at progression by re-
challenge with etoposide 80–100 IV mg/m2 on days 1, 2 and 3 and cisplatin 60–80mg/m2 IV on day 1 or carboplatin AUC 5–6 IV on
day 1, every 21 days. The primary end points were overall survival (OS) and overall response rate to platinum regimen.
RESULTS: Twenty-six patients were enroled and received at least one dose of RRx-001. The median number of prior lines of therapy
was 2 (range 1–9) and 19 (73.1%) patients had platinum-resistant disease. In the intention-to-treat population, one patient (3.8%)
had complete response and six (23.1%) had partial response on platinum plus etoposide. The estimated median and 12-month OS
from enrolment were 8.6 months and 44.1%, respectively. The most common treatment-emergent adverse event from RRx-001 was
mild discomfort at the infusion site (23%).
CONCLUSIONS: RRx-001 followed by re-challenge with platinum plus etoposide chemotherapy is feasible and associated with
promising results.
CLINICAL TRIAL REGISTRATION: NCT02489903.
British Journal of Cancer (2019) 121:211–217; https://doi.org/10.1038/s41416-019-0504-8
BACKGROUND
Small-cell lung cancer (SCLC) accounts for approximately 13% of
all cases of lung cancer in the United States and is characterised
by rapid growth and early development of metastatic disease.1
Despite excellent response to first-line platinum-based che-
motherapy regimens, the majority of patients with limited-stage
disease and virtually all patients with extensive-stage disease
develop tumour progression.2 The strongest predictor for out-
comes in patients with tumour progression after first-line
chemotherapy in SCLC is the duration of response. Outcomes in
subsequent lines of therapy, including response rates and survival,
are better for patients with platinum-sensitive disease, defined as
relapse more than 3 months from completion of initial therapy,
than in those with platinum-refractory or resistant disease, defined
as progression during initial therapy or relapse within 3 months
from completion of the initial therapy. Patients with tumour
relapse 6 or more months after completion of first-line therapy,
may benefit from repeating treatment with the original platinum-
based regimen.3–5 Although the addition of atezolizumab to
platinum and etoposide was associated with a modest improve-
ment in overall survival (OS) compared with chemotherapy alone
in the first-line setting, there are no data on the use of this
regimen in previously treated patients.6
Topotecan is the only approved drug in the second-line setting
for SCLC.7 Among patients treated with topotecan in a large ran-
domized clinical trial, the response rates, median progression-free
survival (PFS) and OS were 23.1%, 4.3 months and 9 months,
respectively, in those with chemotherapy-sensitive disease and
9.4%, 2.6 months and 5.7 months, respectively, in those with
chemotherapy-resistant disease. Nivolumab, a monoclonal anti-
body against programmed death receptor-1 (PD-1), was approved
by the Food and Drug Administration for patients with SCLC
progressing after platinum-based chemotherapy and at least one
other line of therapy, based on the results of the CheckMate-032
study, where, among the 98 patients enroled, the response rate,
median PFS and 1-year PFS were 10%, 1.4 months and 11%,
respectively.8 The overall lack of survival improvement for SCLC
over the past three decades indicates a clear need for novel
treatment approaches.9,10
RRx-001 is a dinitroazetidine derivative that, once injected
intravenously, rapidly penetrates red blood cells (RBCs), where it
binds to the haemoglobin β-chain cysteine 93 residue (Cys-β93),
forming stable adducts, and reduces gluthatione.11,12 RRx-001 is
associated with pleiotropic effects, including upregulation of
oxidative stress, epigenetic modulation and macrophage polarisa-
tion to M1 phenotype. In the phase 1 study, which included 25
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patients with advanced-stage solid tumours, RRx-001 was well
tolerated over six dose cohorts ranging from 10 to 83mg/m2
administered intravenously once or twice per week, with no dose-
limiting toxicities and no treatment-related deaths.13 The most
common adverse events in the phase 1 study were pain at the
infusion site and arm swelling, which occurred in 21 patients
(84%) and 8 patients (32%), respectively. Due to the epigenetic
and immunologic effects, we postulated that RRx-001 may re-
sensitise the tumours to platinum-based chemotherapy.
QUADRUPLE THREAT is an exploratory open-label phase 2 study
evaluating the use of RRx-001 priming followed by re-challenge
with platinum-based chemotherapy in patients with previously
treated SCLC, EGFR mutated non-small-cell lung cancer (NSCLC),
high-grade neuroendocrine tumours and ovarian tumours. Here,
we report the initial cohort of patients with SCLC.
METHODS
Patients
Patients 18 years or older with histologically or cytologically
confirmed small-cell lung carcinoma, previously treated with a
platinum-based chemotherapy regimen, were eligible if they had
tumour relapse within 6 months from completion of the last cycle
of first-line chemotherapy and/or received two or more lines of
prior therapy. Other key eligibility criteria included radiologically
measurable disease by Response Evaluation Criteria in Solid
Tumour (RECIST) 1.1,14 Eastern Cooperative Oncology Group
(ECOG) performance status 0 to 2, adequate haematologic, renal
and hepatic function, and no other current active malignancy
requiring anticancer therapy. Patients with symptomatic brain
metastases, history of severe hypersensitivity to a platinum drug
or use of platinum therapy on more than three separate lines of
therapy for advanced disease were excluded from the study.
Tumour progression within 3 months from the last cycle of first-
line platinum-based chemotherapy was classified as platinum-
resistant disease, whereas progression more than 3 months from
completion of first-line therapy was classified as platinum-
sensitive disease.
The study was approved by the Institutional Review Board at
each of the participating sites and conducted in accordance with
the principles of good clinical practice and the declaration of
Helsinki. All patients provided written informed consent prior to
treatment initiation.
Treatment plan
Patients received 4mg of RRx-001, mixed and co-infused
intravenously with 12ml of their own blood over 10–30minutes
once weekly. The dose of 4 mg was chosen due to the lack of
dose-related efficacy and feasibility of administration, since with a
1 to 5 dilution of drug to blood only 10 ml of blood would be
required for 4 mg whereas a 10mg dose would require 50 ml of
blood, which could increase the risk of clotting and haemolysis
prior to the infusion. The co-infusion was initially performed
through an intravenous bag, which was subsequently changed to
an infusion device after a protocol amendment. The bagless
device comprised a multi-position stopcock to which three
syringes were attached, intravenous tubing, a filter and a needle
for removal of blood. With this approach, the infusion time was
decreased from approximately 60minutes to approximately
15minutes. Premedication was administered within 10–50min-
utes prior to each RRx-001 infusion and included dexamethasone
10mg, administered either orally or intravenously, and acetami-
nophen 500mg or aspirin 81 mg, administered orally.
Treatment with RRx-001 was continued until the development
of tumour’s radiologic or clinical progression or unacceptable
toxicity, with each cycle defined as three weekly treatments.
Contrast-enhanced computed tomography scans were initially
performed every 12 weeks. Nevertheless, the imaging frequency
was changed to every 6 weeks or earlier according to the
investigator’s discretion, after a protocol amendment for both
RRx-001 priming and platinum re-introduction. At the time of
tumour progression or clinical deterioration on RRx-001, patients
started a re-challenge with etoposide 80–100 mg/m2 on days 1 to
3 and either cisplatin 60–80mg/m2 on day 1 or carboplatin AUC
5–6 on day 1 for up to a total of six cycles, followed by close
observation. Dose reductions of RRx-001 to 2mg (first reduction)
and 0.5 mg (second reduction) were allowed in case of infusion
reactions and any grade 3 or 4 drug-related toxicity per the
investigator’s discretion. Dose modifications of the platinum
doublets were performed according to institutional guidelines
and at the discretion of the investigator. Adverse events (AEs)
were categorised and graded according to the National Cancer
Institute Common Terminology Criteria for Adverse Events (NCI-
CTCAE) version 4.03.
The primary end points were OS, defined as the time from study
enrolment until death from any cause, and overall response rate
(ORR) to platinum plus etoposide, defined as the proportion of
patients that achieved a best overall response of complete
response (CR) or partial response (PR) by RECIST 1.1 criteria, both
in the intention-to-treat population (ITT). Confirmation of
responses was not required for the primary end point. Secondary
end points included PFS, defined as the time from study
enrolment to tumour progression on platinum plus etoposide or
death (whichever comes earlier), PFS1 and PFS2, defined as
progressive disease or death on RRx-001 and platinum plus
etoposide, respectively, disease control rate (DCR) for RRx-001 and
chemotherapy, defined as CR, PR or stable disease (SD) and
toxicity. Time-to-event end points were summarised using the
Kaplan−Meier method, with patients who were lost to follow-up
censored at the time of the last contact. Overall response rate was
summarised by the number and percent of patients with partial or
complete response, along with the 95% confidence interval (CI)
based on the Clopper−Pearson method. All analyses were
performed in R statistical software package version 3.5 (R Core
Team, 2018).
With the target ORR of 20% or higher, which was considered
clinically meaningful and worthy of further evaluation based on
the patient population meeting the eligibility criteria, the initial
part of the study was designed to accrue 26 patients based on an
80% CI and 10% precision. Since the study was considered
exploratory and hypothesis generating, the sample size was not
based on power considerations.
RESULTS
Patient characteristics
Between December 2015 and May 2018, 26 patients with
previously treated SCLC were enroled and received at least one
dose of RRx-001. The median age was 62 years (range 39–83),
most patients were males (54%) and 77% had a baseline ECOG
performance score of 1 (Table 1). All patients had been previously
treated with etoposide plus platinum, either carboplatin or
cisplatin. Eleven patients (42%) were treated with platinum-
based chemotherapy as their last line of therapy prior to
enrolment. Eight patients (31%) received more than one course
of platinum-based chemotherapy. Nineteen patients (73.1%) were
resistant to first-line chemotherapy and the median number of
prior lines of therapy was 2 (range 1–9).
Treatment exposure
The median number of RRx-001 doses prior to starting platinum
plus etoposide was 7.8 (range 3–24). No patients required dose
reduction for RRx-001 and radiological or clinical progression was
the reason for treatment discontinuation in all cases. The median
number of cycles of platinum plus etoposide was three
(range 0–6). The reasons for treatment discontinuation of
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platinum-doublet chemotherapy included progressive disease
(PD), fatigue, weight loss, dysphagia, hypotension, depression
and intracranial bleeding from known brain metastasis.
Efficacy
Among the 26 patients enroled into the study, 23 were evaluable
for radiographic responses to RRx-001 and 19 were evaluable for
platinum plus etoposide. There were three patients not evaluable
for response to RRx-001 and seven for platinum plus etoposide,
including the three patients who discontinued therapy prior to
starting the chemotherapy, due to non-compliance, rapid
progression or discontinuation of the treatment before repeated
imaging could be performed.
In the ITT analysis, one patient achieved PR (3.8%, 95%
confidence interval [CI] 0.1−19.6%), seven patients achieved SD
(26.9%, 95% CI 11.6–47.8%) and fifteen patients had PD (57.7%,
95% CI 36.9–76.6%) as the best response during treatment with
RRx-001. Response rates to subsequent platinum plus etoposide in
the ITT analysis included one CR (3.8%, 95% CI 0.1–19.6%) and
six PRs (23.1%, 95% CI 8.9–43.3%), for an ORR of 26.9% (95%
CI 11.6–47.8%). Nine patients achieved SD (34.6%, 95% CI
17.2–55.7%) and three patients had PD (11.5%, 95% CI
2.4–25.1%). The best overall responses to platinum plus etoposide
are described in Fig. 1.
With a median follow-up of 7.3 months (range 1.5–30.1 months),
the median OS was 8.6 months (95% CI 5.8−not reached [NR])
(Fig. 2). The estimated 6-month and 12-month OS was 66.2% and
44.1%, respectively.
The median PFS from the first dose of RRx-001 to trial
discontinuation due to clinical or radiologic-based progressive
disease on platinum plus etoposide or death was 7.5 months (95%
CI: 5.8–NR) (Fig. 3a), whereas the median PFS from platinum plus
etoposide (PFS2) was 6.2 months (95% CI: 3.7–NR) (Fig. 3b). The
median PFS from RRx-001 (PFS1) was 1.3 months. Since the initial
data showed a low probability of tumour control during the
induction RRx-001, 12 patients underwent CT scans after the first
cycle and proceeded to platinum plus etoposide in case of tumour
growth and were considered to have PD even if it did not meet
the RECIST criteria for tumour progression in an attempt to
decrease the probability of rapid clinical deterioration. The
duration of benefit from each patient is shown in Fig. 4.
Since patients with platinum-resistant disease treated in the
third line or beyond are the least likely to benefit from currently
available treatment, we performed an exploratory analysis in this
patient population. There were 14 patients, of whom 9 (64.2%)
received subsequent platinum plus etoposide. Three of the 14
patients (21.4%) achieved PR and 4 (28.5%) had SD. The median
PFS and OS were 5.8 months (95% CI 2.1–NR) and 8.6 months
(95% CI 4.8–NR), respectively.
Safety and tolerability
The most common treatment-emergent adverse events for RRx-
001 included infusion site reaction (23%), decreased appetite
(15.3%) and headache (11.5%), none considered drug related
(Table 2). Infusion site reactions were characterised by a
temporary discomfort at infusion site, paresthesias, pruritus or
cough. There were four grade 3 or 4 toxicities, including decreased
appetite, hypomagnesemia, hyperglycaemia and musculoskeletal
pain. Four patients (15.3%) developed suspected tumour pseudo-
progression during RRx-001 treatment, associated with pain and
tumour size increase by scans, which were followed by improve-
ment in symptoms and either tumour stabilisation or reduction
with continued RRx-001 therapy.
Table 1. Baseline characteristics of 26 patients
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Fig. 1 Best overall response to rechallenge with platinum plus etoposide
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Among patients treated with platinum plus etoposide, grade 1
and 2 adverse events (AEs) occurring in more than 5% of patients
included nausea (61%), constipation (23%), diarrhoea (19%),
abdominal pain (12%), vomiting (7.5%), stomatitis (8%), fatigue
(31%), hypomagnesemia (8%), back pain (8%), musculoskeletal
pain (12%), dyspnoea (12%), cough (7.5%), alopecia (8%) and
thrombocytopenia (8%). Grade 3 and 4 AEs occurring in more than
5% of patients included anaemia (11.5%) and neutropenia (8%).
DISCUSSION
Our study showed that RRx-001 is well tolerated and associated
with subsequent response to platinum plus etoposide in a
previously treated SCLC patient population where benefit from
systemic therapy is uncommon and of short duration. The results
are particularly encouraging in patients with platinum-resistant
disease treated in third-line or beyond, for whom the limited
available data indicates that standard therapy has not been
effective.
There is limited information on the efficacy of third-line
systemic therapy for SCLC, with most data derived from
retrospective studies. In a retrospective multicenter analysis
including 120 patients with SCLC, the response rate to third-line
chemotherapy was 18%, with median PFS and OS of 2.0 months
and 4.7 months, respectively.15 Nevertheless, the patient
population was very selected, with median PFS from first-line
therapy of 9 months. Among the 41 patients with platinum-
resistant disease, only 3 (7%) responded to third-line therapy.
Similar results were observed in a larger retrospective study
including 484 patients, with response rates, median PFS and OS
of 15.1%, 2.0 months and 4.0 months, respectively.16 In a
prospective study with the antibody−drug conjugate targeting
trop-2 sacituzumab govitecan involving 50 patients, the ORR in
patients platinum-resistant, and third-line and beyond were 16
and 17%, respectively.17
Rechallenge treatment with the original first-line platinum
regimen has been studied mostly in patients with platinum-
sensitive disease treated in the second-line setting. In a small
study randomising 57 patients to second-line amrubicin or re-
challenge with a platinum doublet in patients with platinum-
sensitive disease, the ORR was 67% for amrubicin and 43% for
re-challenge with platinum doublet, with median PFS of 5.4 and
5.1 months, respectively.18 Nevertheless, among the 11 patients
with relapse between 3 and 6 months and treated with re-
challenge platinum doublet, only three (27.2%) achieved
response.
The ex-vivo method with the co-administration of RRx-001 with
the patient’s own blood was introduced to mitigate the burning
pain and vasodilation at the infusion site, which was observed in
the phase 1 study, even in the lower dose cohorts, and caused by
the displacement of nitric oxide (NO) from its binding site by RRx-
001.13 Although the infusion site pain was not serious, it led to
patient discomfort and the requirement of prolonged infusion
times. Upon mixing RRx-001 with an aliquot of autologous blood,
NO reenters the red blood cells prior to the infusion, resulting in a
decreased direct contact with the vascular lumen. This method
allowed RRx-001 to be infused in less than 1 h and with decreased
pain at the administration site compared with the phase 1 study.
There are several possible mechanisms to explain the
priming effect for RRx-001. One likely effect is the release of
NO into the hypoxic tumour microenvironment. RRx-001 forms
stable adducts with Cys-β93, which is the binding site for NO on
haemoglobin. Binding of RRx-001 to Cys-β93 leads to NO
displacement from haemoglobin. Although NO has been
associated with tumour growth, through increasing vascular
permeability, stimulating angiogenesis and invasiveness,19,20 it
also induces apoptosis in tumour cells,21,22 particularly at
higher levels.23 Chemotherapy resistance in hypoxic tumour
cells can be attenuated by low concentrations of NO mimetics
such as isosorbide dinitrate in an effect that is at least partly
mediated by inhibition of the NFkB anti-apoptotic
pathway.24,25
Another possible antitumor effect of RRx-001 is epigenetic
modulation. In preclinical models, RRx-001 decreased the levels of
DNA methyltransferases (DNMTs) in colon cancer and multiple
myeloma cells.26,27 Furthermore, a study on murine squamous cell
carcinoma of the head and neck (SCC VII) model showed
decreased global 5-methylcytosine levels, decreased protein
expression of DNMT1 and DNMT3, and increased acetylation of
histones H3 and H4 after treatment with RRx-001, suggesting its
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Fig. 2 Kaplan−Meier estimates for overall survival
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In a phase I/II study involving 45 patients with previously
treated NSCLC, treatment with subcutaneous azacytidine and the
histone deacetylase (HDAC) inhibitor entinostat, the response rate
was 4%.29 However, among the 19 patients that received
subsequent therapy, four achieved major responses suggesting
chemotherapy sensitisation. A similar finding was observed in the
phase 1 study with RRx-001 where although only one of the 21
evaluable patients achieved PR (5%), four patients were subse-
quently re-challenged with previously effective chemotherapy
regimens after progression on RRx-001 and achieved a prolonged
survival, ranging from 10.0 months to 25.3 months.13
In our study, four patients (15.3%) developed pseudoprogres-
sion during the treatment with RRx-001. This phenomenon
has been attributed to increased intratumoral inflammatory
cell infiltrate or necrosis, occurs in approximately 4% of patients
with solid tumours treated with immune checkpoint blockers,
and prompted the development of the immune-related
response criteria (irRC).30,31 Pseudoprogression was also
observed in the phase 1 trial with RRx-001, where it was
attributed to central necrosis, indicated by decreased density of
pulmonary and non-pulmonary lesions, including hepatic and
renal.13
Our study has several limitations, including a small sample size,
absence of a control group and the lack of predictors for response
to RRx-001. Furthermore, due to its exploratory nature, the sample
size was not based on power considerations. Another limitation is
the fact that seven patients had rapid tumour progression and did
not receive the intended re-challenge with platinum plus etopo-
side. When the study was designed, the number of RRx-001
infusions required to re-sensitise the tumours to platinum plus
etoposide was unclear. However, we observed responses to
platinum re-challenge after ≤3 infusions of RRx-001, and with the
rapid SCLC growth it became clear that the induction phase would
have to be reduced to prevent rapid deterioration in some
patients. Therefore, future studies will employ a short induction
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Based on these encouraging initial results, a randomised phase
3 trial comparing RRx-001 followed by platinum plus etoposide to
standard-of-care chemotherapy in previously treated patients with
SCLC (REPLATINUM) has been initiated (NCT03699956).
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